Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18790794 | 0.94 | MAPT (0.40) | CES1TRPV1CA2 | |
| SCHEMBL21784946 | 0.85 | NPC1 (0.45) | CES1CA2GSK3B | |
| SCHEMBL21784939 | 0.82 | ALDH1A1 (0.50) | CES1CA1CA2GSK3BPLK1 | |
| SCHEMBL18790471 | 0.81 | CES1 (0.62) | CES1TRPV1TPMTCA1CA2 | |
| SCHEMBL11482921 | 0.81 | CES1 (0.50) | CES1RXRARXRB | |
| SCHEMBL9065321 | 0.79 | CES1 (0.66) | CES1 | |
| SCHEMBL36702 | 0.79 | CES1 (0.66) | CES1 | |
| SCHEMBL18790795 | 0.78 | CES1 (0.54) | CES1 | |
| SCHEMBL18790460 | 0.75 | CES1 (0.56) | CES1TRPV1TPMTCA1CA2 | |
| SCHEMBL11491006 | 0.75 | CES1 (0.51) | CES1PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365318-B1 | BENZYL MONOKETALS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2021-01-06 | — | — | EP | disclosed |
| US-20200247916-A1 | BENZIL MONOKETALS AND THE USE THEREOF | MERCK PATENT GMBH (DE) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247916-A1 | BENZIL MONOKETALS AND THE USE THEREOF | BCKDK, PKLR, BPHL | CES1 1215/4885TRPV1 214/4885TPMT 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.